72 related articles for article (PubMed ID: 21068753)
1. Targeting x-linked inhibitor of apoptosis protein for melanoma therapy: the need for more homogeneous samples and the importance of cell lines.
Kwatra SG
J Invest Dermatol; 2011 Mar; 131(3):797. PubMed ID: 21068753
[No Abstract] [Full Text] [Related]
2. Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy.
Hiscutt EL; Hill DS; Martin S; Kerr R; Harbottle A; Birch-Machin M; Redfern CP; Fulda S; Armstrong JL; Lovat PE
J Invest Dermatol; 2010 Sep; 130(9):2250-8. PubMed ID: 20520630
[TBL] [Abstract][Full Text] [Related]
3. The pathway ahead in melanoma trials.
Miller AJ; Markovic SN; Haluska P
Oncology (Williston Park); 2009 May; 23(6):496, 498, 500. PubMed ID: 19544690
[No Abstract] [Full Text] [Related]
4. Progression of NRAS and BRAF mutations in cutaneous melanoma.
Rosso R; Romagosa Y; Kirsner RS
J Invest Dermatol; 2009 Jun; 129(6):1318. PubMed ID: 19434085
[No Abstract] [Full Text] [Related]
5. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
6. Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
Kim YK; Ahn SK; Lee M
Cancer Lett; 2012 Jul; 320(2):215-24. PubMed ID: 22425959
[TBL] [Abstract][Full Text] [Related]
7. NFATc2 is a potential therapeutic target in human melanoma.
Perotti V; Baldassari P; Bersani I; Molla A; Vegetti C; Tassi E; Dal Col J; Dolcetti R; Anichini A; Mortarini R
J Invest Dermatol; 2012 Nov; 132(11):2652-60. PubMed ID: 22718120
[TBL] [Abstract][Full Text] [Related]
8. [Melanoma and search for therapeutic targets].
de la Fouchardière A
Ann Pathol; 2011 Nov; 31(5 Suppl):S123-4. PubMed ID: 22054449
[No Abstract] [Full Text] [Related]
9. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
[TBL] [Abstract][Full Text] [Related]
10. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma.
Nickoloff BJ; Vande Woude G
Pigment Cell Melanoma Res; 2012 Nov; 25(6):758-61. PubMed ID: 22974232
[No Abstract] [Full Text] [Related]
12. Targeting NRAS in melanoma.
Kelleher FC; McArthur GA
Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
[TBL] [Abstract][Full Text] [Related]
13. Detection of B-RAF and N-RAS mutations in human melanoma.
Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
[TBL] [Abstract][Full Text] [Related]
14. Spindle cell squamous carcinoma during BRAF inhibitor therapy for advanced melanoma: an aggressive secondary neoplasm of undetermined biologic potential.
Cohen DN; Lumbang WA; Boyd AS; Sosman JA; Zwerner JP
JAMA Dermatol; 2014 May; 150(5):575-7. PubMed ID: 24577111
[No Abstract] [Full Text] [Related]
15. Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF.
Christensen C; Guldberg P
Oncogene; 2005 Sep; 24(41):6292-302. PubMed ID: 16007203
[TBL] [Abstract][Full Text] [Related]
16. Targeting oncogenic drivers and the immune system in melanoma.
McArthur GA; Ribas A
J Clin Oncol; 2013 Feb; 31(4):499-506. PubMed ID: 23248252
[TBL] [Abstract][Full Text] [Related]
17. Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy.
Mohana-Kumaran N; Hill DS; Allen JD; Haass NK
Pigment Cell Melanoma Res; 2014 Jul; 27(4):525-39. PubMed ID: 24655414
[TBL] [Abstract][Full Text] [Related]
18. Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation.
Houben R; Ortmann S; Drasche A; Troppmair J; Herold MJ; Becker JC
J Invest Dermatol; 2009 Feb; 129(2):406-14. PubMed ID: 18650848
[TBL] [Abstract][Full Text] [Related]
19. A new standard of care for metastatic melanoma?
Sharma SP
Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
[No Abstract] [Full Text] [Related]
20. A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanoma?
Lade-Keller J; Kristensen LS; Riber-Hansen R; Guldberg P; Hansen LL; Steiniche T; Hager H
J Clin Pathol; 2013 Aug; 66(8):723-5. PubMed ID: 23526598
[No Abstract] [Full Text] [Related]
[Next] [New Search]